pharmaphorum

DECEMBER 8, 2014

With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what is next, what are the ramifications for high priced/innovative treatments delivering beneficial outcomes to defined patient populations in the UK and how can pharma navigate seemingly choppy waters of access for rare disease treatments and orphan drugs?

52

52

pharmaphorum

OCTOBER 29, 2014

Non-adherence to self-management regimens in diabetes is globally a widespread, costly and ultimately life threatening issue. Reasons for non-adherence are complex as the nature of the condition involves adherence to lifestyle, medication and diet changes, which individuals at times can find difficult to accept and adjust to. It is important to consider that the factors that influence each individual's ability to self manage are often very different and can equally affect patient outcomes, makin

Diabetes 52

Diabetes 52

pharmaphorum

OCTOBER 22, 2014

A pharmaceutical industry multi-stakeholder interactive discussion on some of the unique challenges faced today in marketing pharma brands effectively to exploit areas of unrealised opportunity, plus what is required from both strategic marketing and research to deliver in view of this.

52

52

pharmaphorum

JULY 9, 2014

The global pharmaceutical market passes a significant milestone in 2014: reaching one trillion US dollars in total value. IMS Health forecasts the global market will see a compound average growth rate of between 4 to 7 percent in constant dollar terms to 2018, driven by two very different speed growth engines: at best low single digit value growth in the developed markets, contrasting with largely double digit growth in the power house pharmerging markets.

Compounding 52

Compounding 52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.